Samuel Bates Martin
Known title: SVP and CFOCIK: 0001709024
Associated companies
Transaction History
| CLDX | ▲ Buy | Option Exercise | 4,817 | $50K | 1/2/2026 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 3,201 | $29K | 6/14/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 16,968 | $176K | 6/14/2024 | View on chart |
| CLDX | ▼ Sell | Open Market | 17,172 | $608K | 6/14/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 25,000 | $260K | 5/30/2024 | View on chart |
| CLDX | ▼ Sell | Open Market | 35,000 | $1.2M | 5/30/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 10,750 | $30K | 1/2/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 3,876 | $35K | 8/12/2022 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 13,671 | $38K | 8/12/2022 | View on chart |
| CLDX | ▼ Sell | Open Market | 14,261 | $524K | 8/12/2022 | View on chart |
| CLDX | ▼ Sell | Open Market | 2,065 | $73K | 8/12/2022 | View on chart |
| CLDX | ▼ Sell | Open Market | 1,221 | $42K | 8/12/2022 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 2,453 | $22K | 8/11/2022 | View on chart |
| CLDX | ▼ Sell | Open Market | 2,453 | $91K | 8/11/2022 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 3,250 | $29K | 12/23/2021 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 3,750 | $10K | 12/23/2021 | View on chart |
| CLDX | ▼ Sell | Open Market | 9,500 | $399K | 12/23/2021 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 3,750 | $10K | 11/15/2021 | View on chart |
| CLDX | ▼ Sell | Open Market | 2,048 | $87K | 11/15/2021 | View on chart |
| CLDX | ▼ Sell | Open Market | 7,452 | $327K | 11/15/2021 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 3,250 | $29K | 11/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Celldex shares dip after positive Phase 3 barzolvolimab results
Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.
Celldex shares dip after positive Phase 3 barzolvolimab results. Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.